Shopping Cart
Remove All
Your shopping cart is currently empty
Vamifeport (VIT-2763) is a novel orally active inhibitor that targets iron transport proteins and reduces markers of hemolysis in the SCD Townes model.VIT-2763 improves anemia and erythropoiesis, ameliorates vascular inflammation, and can be studied in β-thalassemia.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $67 | 7-10 days | 7-10 days | |
| 5 mg | $162 | 7-10 days | 7-10 days | |
| 10 mg | $243 | 7-10 days | 7-10 days | |
| 25 mg | $397 | 7-10 days | 7-10 days | |
| 50 mg | $575 | 7-10 days | 7-10 days | |
| 100 mg | $786 | 7-10 days | 7-10 days | |
| 200 mg | $1,080 | 7-10 days | 7-10 days | |
| 1 mL x 10 mM (in DMSO) | $177 | - | In Stock |
| Description | Vamifeport (VIT-2763) is a novel orally active inhibitor that targets iron transport proteins and reduces markers of hemolysis in the SCD Townes model.VIT-2763 improves anemia and erythropoiesis, ameliorates vascular inflammation, and can be studied in β-thalassemia. |
| In vitro | Treatment with VIT-2763 (20μM) or hepcidin (1μM) for 20 minutes, 1 hour, 3 hours, 6 hours, and 18 hours induced dose-dependent internalization and ubiquitination of iron transporters in MDCK cells[1]. |
| In vivo | VIT-2763 (30, 100 mg/kg; orally twice daily for 36 days) restricted iron availability, ameliorating anemia and iron homeostasis dysregulation in the intermediate β-thalassemia Hbbth3/+ mouse model, improving erythropoiesis and correcting the proportion of myeloid precursors in the spleen of Hbbth3/+ mice[1]. |
| Synonyms | VIT-2763 |
| Molecular Weight | 408.43 |
| Formula | C21H21FN6O2 |
| Cas No. | 2095668-10-1 |
| Smiles | Fc1cccnc1CNC(=O)c1coc(CCNCCc2nc3ccccc3[nH]2)n1 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 70 mg/mL (171.39 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (4.9 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.